Current immunosuppressant regimens: Considerations for critical care

Current Opinion in Critical Care

Volumn 7, Issue 4, 2001, Pages 242-250

  Kahan, Barry D ^a   Koch, Stephen M ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; ALPRAZOLAM; AMLODIPINE; ASTEMIZOLE; ATORVASTATIN; CARBAMAZEPINE; CISAPRIDE; CLARITHROMYCIN; CLOTRIMAZOLE; CYCLOSPORIN A; DANAZOL; DIAZEPAM; ERYTHROMYCIN; EVEROLIMUS; FELODIPINE; FENTANYL; FINGOLIMOD; FLUCONAZOLE; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; NICARDIPINE; PHENOBARBITAL; PHENYTOIN; RAPAMYCIN; TACROLIMUS; TERFENADINE; TROLEANDOMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

BRADYCARDIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; GRAFT SURVIVAL; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE UNIT; LEUKOPENIA; NEPHROTOXICITY; ORGAN TRANSPLANTATION; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME;

CRITICAL CARE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TRANSPLANTATION IMMUNOLOGY;

EID: 0034835020     PISSN: 10705295     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075198-200108000-00006     Document Type: Review

References (66)

1. Cyclosporin A in patients receiving renal allografts from cadaver donors
2. Liver transplantation with use of cyclosporin and prednisone
3. Improved graft survival after renal transplantation in the United States, 1988 to 1996
4. FK 506 for liver, kidney, and pancreas transplantation
5. Established immunosuppressive drugs: Clinical and toxic effects
6. The mode of action of Prograf (tacrolimus) and its significance for long-term graft survival
7. The pharmacokinetics of cyclosporine A in uremic patients
8. Overview: Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters
9. Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy
10. Cyclosporine pharmacokinetics and variability from a microemulsion formulation - A multicenter investigation in kidney transplant patients
11. Cyclosporine
12. Practical aspects in the use of cyclosporin in paediatric nephrology
13. Pharmacokinetics of oral cyclosporin A in diabetic children and adolescents
14. Concentrations of cyclosporin A and its metabolites in human tissues postmortem
15. Effect of hepatic dysfunction and T-tube clamping on FK506 pharmacokinetics and trough concentrations
16. The value of serial serum trough cyclosporine levels in human renal transplantation
17. Relationship of pharmacokinetics to clinical outcomes
18. Absorption profiling: A novel method for monitoring Neoral in kidney transplantation that reduces rejection and nephrotoxicity
19. Abbreviated AUC strategy for monitoring cyclosporine microemulsion therapy in the immediate posttransplant period
20. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation
21. Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: Racial differences in bioavailability
22. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506
23. A comparison of tacrolimus and cyclosporine for immunosuppression after cadaveric renal transplantation
24. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine
25. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients
26. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody
27. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation
28. Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts
29. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation
30. Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation: The U.S. Simulect Renal Transplant Study Group
31. Determination of humanized anti-Tac in human serum by a sandwich enzyme linked immunosorbent assay
32. Early versus late acute renal allograft rejection: Impact on chronic rejection
33. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation
34. Sirolimus (Rapamune, rapamycin) is more effective than azathioprine to reduce the incidence of acute renal allograft rejection episodes when used in combination with cyclosporine and prednisone: A phase III US multicenter trial
35. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts
36. Rapamycin selectively inhibits interleukin-2 activation of p70 s6 kinase
37. Measurement of rapamycin in whole blood using reverse-phase high-performance liquid chromatography
38. Consensus guidelines for therapeutic drug monitoring of rapamycin: Report of the consensus panel
39. Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry
40. Routine clinical monitoring of sirolimus (rapamycin) whole-blood concentrations by HPLC with ultraviolet detection
41. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration
42. Blood distribution of rapamycin
43. Population pharmacokinetics of sirolimus in kidney transplant patients
44. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat
45. Therapeutic drug monitoring of sirolimus: Correlations with efficacy and toxicity
46. A phase I study of a four-week course of the rapamycin analogue SDZ-RAD (RAD) in quiescent cyclosporine-prednisone-treated renal transplant recipients
47. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: Pharmacokinetics, exposure-response relationships, and influence on cyclosporine
48. Sirolimus: Clinical results and future opportunities
49. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation
50. The side effect profile of sirolimus: A phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients
51. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: Risk factors, incidence, progression, and management
52. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506
53. The synergistic effects of cyclosporine and sirolimus
54. Sirolimus vs. cyclosporine: A comparison of renal function over two years
55. Lipids and progressive renal disease: The cardio-renal link
56. FTY720: A novel transplantation drug that modulates lymphocyte traffic rather than activation
57. Human safety and pharmacology of FTY720
58. FTY720 combined with Neoral and corticosteroids is effective and safe in prevention of acute rejection in renal allograft recipients (interim data)
59. FTY720 suppresses immune responses by modulating G-protein coupled receptors on lymphocytes resulting in altered lymphocyte homing
60. Safety and pharmacodynamics of multiple doses of FTY720
61. Immunosuppressive effects of FTY720 alone or in combination with cyclosporine or sirolimus
62. Prophylaxis of acute renal allograft rejection using FTY720 in combination with subtherapeutic doses of cyclosporine
63. Trough levels and concentration time curves of cyclosporine in patients undergoing renal transplantation
64. Pretransplant test-dose pharmacokinetic profiles: Cyclosporine microemulsion versus corn oil-based soft gel capsule formulation
65. Demographic considerations in tacrolimus pharmacokinetics
66. Rapamycin: Distribution, pharmacokinetics, and therapeutic range investigations